Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update

No abstract is available for this paper.

• Publication year

  2014

• Venue

  AAPS Journal

• Publication date

  2014-09-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1208/s12248-014-9668-6PMID 25236865PMCID PMC4287283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics

  2014cited by this paper
• Interaction of Novel Platelet-Increasing Agent Eltrombopag with Rosuvastatin via Breast Cancer Resistance Protein in Humans

  2014cited by this paper
• Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia

  2014cited by this paper
• ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.

  2013cited by this paper
• Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.

  2013cited by this paper
• CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.

  2013cited by this paper
• Harmful effect of ERβ on BCRP‐mediated drug resistance and cell proliferation in ERα/PR‐negative breast cancer

  2013cited by this paper
• Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.

  2013cited by this paper
• Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients

  2013cited by this paper
• Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance

  2013cited by this paper
• Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening.

  2013cited by this paper
• Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein

  2013cited by this paper
• Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design

  2013cited by this paper
• Predicting substrates of the human breast cancer resistance protein using a support vector machine method

  2013cited by this paper
• Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.

  2013cited by this paper
• Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan

  2013cited by this paper
• Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype.

  2013cited by this paper
• Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.

  2013cited by this paper
• Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.

  2013cited by this paper
• In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters

  2013cited by this paper
• Progesterone Negatively Regulates BCRP in Progesterone Receptor-Positive Human Breast Cancer Cells

  2013cited by this paper
• Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.

  2012cited by this paper
• Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS.

  2012cited by this paper
• Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior

  2012cited by this paper
• Influence of ABCC2, SLCO1B1, and ABCG2 Polymorphisms on the Pharmacokinetics of Olmesartan

  2012cited by this paper
• CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are Determinants of Inter-subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers

  2012cited by this paper
• Expression of ATP-Binding Cassette Membrane Transporters in Rodent and Human Sertoli Cells: Relevance to the Permeability of Antiretroviral Therapy at the Blood-Testis Barrier

  2012cited by this paper
• Quantitative structure-activity relationship (QSAR) analysis to predict drug-drug interactions of ABC transporter ABCG2.

  2012cited by this paper
• Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.

  2012cited by this paper
• Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients

  2012cited by this paper
• Protein structure prediction from sequence variation

  2012cited by this paper
• Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP

  2012cited by this paper
• Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

  2012cited by this paper
• Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia

  2011cited by this paper
• Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.

  2011cited by this paper
• ATP-binding cassette efflux transporters in human placenta.

  2011cited by this paper
• The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers

  2011cited by this paper
• Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level

  2011cited by this paper
• pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein

  2011cited by this paper
• Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.

  2011cited by this paper
• Predicting P-Glycoprotein-Mediated Drug Transport Based On Support Vector Machine and Three-Dimensional Crystal Structure of P-glycoprotein

  2011cited by this paper
• The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients

  2011cited by this paper
• Dimerization of ABCG2 Analysed by Bimolecular Fluorescence Complementation

  2011cited by this paper
• Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway

  2011cited by this paper
• Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed?

  2011cited by this paper
• The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

  2011cited by this paper
• Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

  2010cited by this paper
• Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

  2010cited by this paper
• Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

  2010cited by this paper
• Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.

  2010cited by this paper
• Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib

  2010cited by this paper
• Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.

  2010cited by this paper
• The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.

  2010cited by this paper
• 17-β-Estradiol: A Powerful Modulator of Blood–Brain Barrier BCRP Activity

  2010cited by this paper
• hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations

  2010cited by this paper
• Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.

  2010cited by this paper
• Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells.

  2010cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

  2010cited by this paper
• Proinflammatory Cytokines Enhance Estrogen-dependent Expression of the Multidrug Transporter Gene ABCG2 through Estrogen Receptor and NFκB Cooperativity at Adjacent Response Elements*♦

  2010cited by this paper
• Trichosanthes anguina L. is variety of Trichosanthese cucumerina L. - evidence based on molecular phylogenetic analysis of internal transcribed spacer (ITS) sequences of nuclear ribosomal DNA.

  2010cited by this paper
• Dynamic vs Static ABCG2 Inhibitors to Sensitize Drug Resistant Cancer Cells

  2010cited by this paper
• Role of Basic Residues within or near the Predicted Transmembrane Helix 2 of the Human Breast Cancer Resistance Protein in Drug Transport

  2010cited by this paper
• Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.

  2009cited by this paper
• Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout

  2009cited by this paper
• Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design

  2009cited by this paper
• Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2

  2009cited by this paper
• ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2009cited by this paper
• Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.

  2009cited by this paper
• Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties

  2009cited by this paper
• ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood–Brain Barrier for Aβ1–40 Peptides

  2009cited by this paper
• QSAR analysis and molecular modeling of ABCG2-specific inhibitors.

  2009cited by this paper
• Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.

  2009cited by this paper
• An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)

  2009cited by this paper
• MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells

  2009cited by this paper
• Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

  2009cited by this paper
• Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

  2009cited by this paper
• Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice.

  2009cited by this paper
• Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

  2009cited by this paper
• Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2)

  2009cited by this paper
• Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

  2009cited by this paper
• Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers

  2009cited by this paper
• Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells

  2008cited by this paper
• The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.

  2008cited by this paper
• Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

  2008cited by this paper
• Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers

  2008cited by this paper
• Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line

  2008cited by this paper
• Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.

  2008cited by this paper
• Breast cancer resistance protein expression and 5-fluorouracil resistance.

  2008cited by this paper
• Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

  2008cited by this paper
• Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 (Cancer Research (2008) 68, (7905-7914))

  2008cited by this paper
• Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).

  2008cited by this paper
• Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

  2008cited by this paper
• Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin

  2008cited by this paper
• Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

  2008cited by this paper
• The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

  2008cited by this paper
• Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

  2008cited by this paper
• Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells.

  2008cited by this paper
• The 44-kDa Pim-1 Kinase Phosphorylates BCRP/ABCG2 and Thereby Promotes Its Multimerization and Drug-resistant Activity in Human Prostate Cancer Cells*

  2008cited by this paper
• The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine.

  2007cited by this paper

• ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine.

  2026cites this paper
• Role of the ABCG2 transporter in the biodistribution of the food-borne uremic toxin p-cresyl sulfate.

  2026cites this paper
• Keratinocyte transport of notoginsenoside R1 via ABCG2: A novel mechanism for RNA N6-methyladenosine modification in UVB induced skin sunburn injury.

  2026cites this paper
• French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics

  2026cites this paper
• Hog1 MAP kinase modulates early riboflavin accumulation under low-pH and saline conditions in Debaryomyces hansenii.

  2026cites this paper
• From rumen to milk: Dietary polyphenols in dairy cows—A critical review

  2026cites this paper
• Assessing the role of the ABCG2 transporter in plasma levels and secretion into milk of aflatoxins B2 and G1.

  2026cites this paper
• Biosynthesis, Regulation, and Biotechnological Production Strategies of Riboflavin (Vitamin B2) and Its Derivatives: A Review

  2026cites this paper
• From Nose to Neurons: The Emerging Role of Dissolving Microneedles in Neurodegenerative Disease Management

  2026cites this paper
• Zebrafish Abcg2a mutant line as an in vivo model for evaluation of the interaction of Abcg2a with drugs and contaminants.

  2026cites this paper
• Effect of ABCG2 genetic polymorphisms on the transport of anti-seizure medications in hCMEC/D3 cell lines

  2026cites this paper
• Strategies for overcoming ABC transporter mediated drug resistance in colorectal cancer.

  2025cites this paper
• Expression, Function, and Regulation of ABCG2 on the Intestinal Epithelial Barrier Permeability.

  2025cites this paper
• Phytochemical intervention in BCRP-driven cancer drug resistance: A comprehensive review.

  2025cites this paper
• Carvacrol as a Therapeutic Candidate in Breast Cancer: Insights into Subtype-Specific Cellular Modulation

  2025cites this paper
• In silico evaluation of the anti Helicobacter pylori activity of selected bioactive compounds from Aloe vera

  2025cites this paper
• A Phase 1 Study to Assess the Effect of Fruquintinib on the Pharmacokinetics of P‐gp and BCRP Substrates in Healthy Subjects

  2025cites this paper
• Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist’s perspective

  2025cites this paper
• Inhibitory Effects of Alkaloids on BCRP Implicated in Reversing Multidrug Resistance: A Case Example of Enhancing Temozolomide Cytotoxicity.

  2025cites this paper
• Determination of bioactive and anti-inflammatory molecules of Thymbra spicata L. from Mardin by GC–MS and LC–Orbitrap HRMS: a DFT, molecular docking, ADMET, biological target and activity study

  2025cites this paper
• Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood–Brain Barrier and Blood–Tumor Barrier

  2025cites this paper
• Exploring the impact of high rosuvastatin plasma exposure on new-onset diabetes mellitus: insights from machine learning-based prediction

  2025cites this paper
• Inhibitory potential of phytochemicals on species-specific breast cancer resistance protein transport activity.

  2025cites this paper
• Synthesis, in silico studies and in vitro evaluation of Benzimidazole and Benzotriazole derivatives as efflux pump inhibitors

  2025cites this paper
• Re-sensitization of cancer multidrug resistance through P-gp, MRP1 and BCRP modulation: advances in terpenoids based cancer therapy

  2025cites this paper
• Nanotechnology-based immunotherapy, an emerging paradigm in breast cancer therapeutics.

  2025cites this paper
• Targeting Cancer with Redox Catalysis: Manganese Porphyrins and Ascorbate Synergistically Induce Selective Oxidative Stress and Necrotic Cell Death

  2025cites this paper
• Evaluation of the effect of ethylmethylhydroxypyridine succinate on the activity of the BCRP transporter protein in vitro

  2025cites this paper
• Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf

  2025cites this paper
• Amide linked chalcone derivatives, a promising class of compounds with versatile biological effects

  2025cites this paper
• The combination of rosuvastatin and meloxicam enhances the radiotherapy efficacy of MCF7, T-47D, and MDA-MB-231 breast cancer cell lines

  2025cites this paper
• Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• The Potential Role of Exosomes in Communication Between Astrocytes and Endothelial Cells

  2025cites this paper
• Translational Advances in Oncogene and Tumor-Suppressor Gene Research

  2025cites this paper
• Female breast cancer classification using immunohistochemistry biomarkers staining in Botswana

  2025cites this paper
• Advances in metal ion-mediated macromolecular drug delivery.

  2025cites this paper
• Effect of cannabinoids on the efficacy and side effects of anticancer therapeutic strategies - Current status of preclinical and clinical research.

  2025cites this paper
• In Silico Approach to Design of New Multi-Targeted Inhibitors Based on Quinoline Ring with Potential Anticancer Properties

  2025cites this paper
• Effects of ABCG2 421C > A genetic polymorphism on the pharmacokinetics of rivaroxaban in healthy Chinese subjects

  2025cites this paper
• Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs

  2025cites this paper
• Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance.

  2025cites this paper
• Association between ABCG2 polymorphisms and allopurinol response in gout patients: a systematic review and meta-analysis.

  2025cites this paper
• Elucidating the role of ABC transporters in the placental efflux of (-)- Δ9-tetrahydrocannabinol (THC) using a cocktail of ABC transport inhibitors.

  2025cites this paper
• Transporters and drug secretion into human breast milk

  2025cites this paper
• Dichloroacetate enhances Chemo-sensitivity in wild-type P53 breast cancer cells by modulating ABCG2 and NKG2DL

  2025cites this paper
• Statin use in transthyretin amyloid cardiomyopathy: Assessing tolerability and drug interaction risks with tafamidis.

  2025cites this paper
• MiRNAs: main players of cancer drug resistance target ABC transporters

  2025cites this paper
• Assessing central nervous system drug delivery

  2025cites this paper
• Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications

  2025cites this paper
• SLC6A14 Drives Mitochondrial Fusion and Oxidative Phosphorylation to Promote Cancer Stemness and Early‐Onset of Breast Cancer

  2025cites this paper
• DNA repair and the contribution to chemotherapy resistance

  2025cites this paper
• p38 inhibition restores chemosensitivity of tumor cells by disrupting oligomerized breast cancer resistance protein membrane trafficking

  2025cites this paper
• Impact of organic pollutants on phenotype and gene expression in human breast cancer cells.

  2025cites this paper
• Trends and Hot Spots in Research Related to Rivaroxaban: Bibliometric Analysis

  2025cites this paper
• Effect of proinflammatory cytokines on intestinal drug transporters in human enteroid monolayers.

  2025cites this paper
• Visualization-based evaluation of short-chain PFAS effects on ABCG2 in human cell models: A preliminary study

  2025cites this paper
• The Role of Exosomes as a Key Factor of Cytostatic Resistance in Cancer: Mechanisms of Action, Potential Biomarkers, and Possible Exosome-Based Therapies

  2025cites this paper
• The Role of the Bone Marrow Microenvironment in Leukemic Stem Cell Resistance: Pathways of Persistence and Selection.

  2025cites this paper
• ABCG2 Transporter: From Structure to Function—Current Insights and Open Questions

  2025cites this paper
• Identifying potent ABCG2 inhibitors from the COCONUT database of natural compounds to overcome drug resistance in breast cancer: a comprehensive in silico study targeting ATP-binding cassette (ABC) transporter G2

  2025influential citation
• Gatekeeper of the brain: unraveling the role of ABCB1 in Parkinson’s disease progression and therapy

  2025cites this paper
• In Vitro and In Silico Evaluation of the Anti-Aging Potential of Eugenia uniflora UAE Extracts

  2025cites this paper
• Unraveling Caco-2 Cells through Functional and Transcriptomic Assessments.

  2025cites this paper
• Regulation of adipocyte differentiation and lipid metabolism by novel synthetic chromenes exploring anti-obesity and broader therapeutic potential

  2025cites this paper
• Comparison of new secondgeneration H1 receptor blockers with some molecules; a study involving DFT, molecular docking, ADMET, biological target and activity

  2025cites this paper
• Comparative Analysis of Chemotherapy Resistance Mechanisms in Humans and Companion Animals

  2025cites this paper
• HSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms

  2025cites this paper
• Drug Interactions of Antifungal Agents: Clinical Relevance and Implications

  2025cites this paper
• Method for Testing Drugs Belonging to Substrates and Inhibitors of the Transporter Protein BCRP on CACO-2 Cells

  2025cites this paper
• Membrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies.

  2025cites this paper
• Network pharmacology and in silico approach to study the mechanism of quercetin against breast cancer

  2025cites this paper
• Mycoestrogen Exposure during Pregnancy: Impact of the ABCG2 Q141K Variant on Birth and Placental Outcomes

  2025cites this paper
• Enhanced in-vitro bioavailability of curcumin, lutein and isoflavones through interaction with spearmint (Mentha spicata) via its bioactive component (R)-(-)-carvone.

  2025cites this paper
• Exploring the effect of intracellular loop 1 genetic variants in human ABCG2 on transport activity and protein abundance.

  2025cites this paper
• In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

  2025cites this paper
• Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies

  2024cites this paper
• Modulation of Multispecific Transporters by Uncaria tomentosa Extract and Its Major Phytoconstituents

  2024cites this paper
• TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer

  2024cites this paper
• Medicinal plants as a potential resource for the discovery of novel structures towards cancer drug resistance treatment

  2024cites this paper
• Multidrug Resistance Reversed by Maleimide Interactions. A Biological and Synthetic Overview for an Emerging Field

  2024cites this paper
• The Role of ABCB1, ABCG2, and SLC Transporters in Pharmacokinetic Parameters of Selected Drugs and Their Involvement in Drug–Drug Interactions

  2024cites this paper
• The association of ABC proteins with multidrug resistance in cancer.

  2024cites this paper
• Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug–Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers

  2024cites this paper
• Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer

  2024influential citation
• Role of the RNA binding protein IGF2BP1 in cancer multidrug resistance.

  2024cites this paper
• 1,2,3-Triazole Nilotinib Analogues: Synthesis and Cytotoxic Activity

  2024cites this paper
• The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney

  2024cites this paper
• Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review

  2024cites this paper
• Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH.

  2024cites this paper
• ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches

  2024cites this paper
• Application of a Novel UPLC-MS/MS Method for Analysis of Rivaroxaban Concentrations in Dried Blood Spot and Plasma Samples Collected from Patients with Venous Thrombosis

  2024cites this paper
• lncRNAs: New players of cancer drug resistance via targeting ABC transporters

  2024cites this paper
• The ABCG2 Transporter Affects Plasma Levels, Tissue Distribution and Milk Secretion of Lumichrome, a Natural Derivative of Riboflavin

  2024cites this paper
• Oncostatin M reverses ABCG2-mediated mitoxantrone resistance.

  2024cites this paper
• In vitro screening model for compound interactions with human and dairy animal BCRP orthologs.

  2024cites this paper
• Enhancing PDT efficacy in NMIBC: Efflux inhibitor mediated improvement of PpIX levels and efficacy of the combination of PpIX‐PDT and SO‐cleavable prodrugs

  2024cites this paper
• Purpurogallin carboxylic acid exhibits synergistic effects with 5‑fluorouracil on liver cancer cells in vitro by targeting ABCG2

  2024cites this paper
• Efflux transporters in drug disposition during pregnancy.

  2024cites this paper
• Breast Cancer Resistance Protein: Structure, Localization, Functions, Significance for Rational Pharmacotherapy

  2024cites this paper
• Recent Strategies to Overcome Breast Cancer Resistance.

  2024cites this paper